Navigation Links
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Date:6/16/2008

Data published in the Journal of the American Society of Hypertension

demonstrate that early blockade of angiotensin II reversed vascular

hypertrophy

PARSIPPANY, N.J., June 16 /PRNewswire/ -- A new study published in the current Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, titled VIOS (Vascular Improvement with Olmesartan medoxomil Study) was a one-year, exploratory study that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.(1)

In the VIOS trial, olmesartan medoxomil, through early blockade of angiotensin II, improved the structure abnormalities of resistance arteries in patients with hypertension as measured by arterial wall to lumen ratio (W/L), returning arterial architecture to normal levels after one year of treatment. This protective effect was not seen with the comparator agent in the study, atenolol.(2) Olmesartan medoxomil is marketed in the United States by Daiichi Sankyo, Inc., as BENICAR(R). BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy. BENICAR and BENICAR HCT have not been FDA approved for other indications such as end organ disease or other hypertension related morbidity.

"We believe the VIOS data add to the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular damage at many stages during this disease process," said Carlos M. Ferrario, M.D., one of the study's lead inve
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Pharmaxis Long-Term Safety Study of Bronchitol Completes
4. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
7. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
10. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
11. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... PLAINFIELD, N.J., Feb. 17, 2011 Dr. Abraham Abuchowski, ... by the U.S. Small Business Administration on February 15 ... and job creation. Dr. Abuchowski was one of eight ... industry. Dr. Abuchowski was the originator ...
... Symmetry Medical Inc. (NYSE: SMA ), a ... industry and other medical markets, announced today preliminary unaudited revenue ... Symmetry anticipates full year 2010 revenue of approximately $361 ... $364 million. For the full year 2011, ...
Cached Medicine Technology:Dr. Abraham Abuchowski of Prolong Pharmaceuticals Honored With Inaugural Tibbetts Award by the U.S. Small Business Administration 2Symmetry Medical Announces Preliminary Unaudited Full Year 2010 Revenue 2Symmetry Medical Announces Preliminary Unaudited Full Year 2010 Revenue 3
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Though most patients ... medication and therapy, between 10 percent to 20 percent ... to standard care, experts say. However, patients with ... form of a type of brain surgery that disables ... The challenge: to distinguish between patients most likely to ...
(Date:12/24/2014)... you are a high-risk heart patient, you might be ... cardiologist, new research suggests. Survival rates among these ... professional meetings, Harvard researchers report. Sixty percent of ... teaching hospital during one of these meetings died within ... were not taking place. "That,s a tremendous reduction ...
(Date:12/22/2014)... December 22, 2014 As part ... senior care service in San Diego and ... of its senior care team with ongoing online ... Golden Care is provided by Caregiverlist®. Caregiverlist® ... caregivers with the most reliable eldercare options, highest ...
(Date:12/22/2014)... Los Angeles, CA (PRWEB) December 22, 2014 ... the names have changed. The reason why most fad ... work - temporarily. The problem with fad diets is that, ... loss tapers, leaving the dieter uncertain of how to reset ... mode. For this reason, Diet Doc developed their all-inclusive ...
Breaking Medicine News(10 mins):Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4
... Minyard Food Stores Inc. is offering any,expectant mom ... Life Healthy(TM)" initiative, the company announced,today., Just in ... will,offer free prenatal vitamins to all expectant mothers for ... any Carnival, Minyard or,Sack,n Save store in North Texas. ...
... and other hospital and healthcare advocates from across the,state ... protest the nearly $300,million in healthcare cuts proposed in ... Gone Tomorrow," a Rally to Preserve Our Healthcare, ... WHEN: 12 noon, May 12, The "Care Today, ...
... Consumer,Healthcare, marketer of the leading smoking cessation products ... applauds,the release of the updated 2008 U.S. Public ... Dependence. Too many smokers lower their,chances of quitting ... The Guideline is an important validation of the ...
... Vaccinogen Inc. said Dutch health,authorities licensed it to manufacture ... to more than $100 million of,potential European sales., ... Emmen, The,Netherlands also paves the way to its pivotal ... before the vaccine can be sold in the United,States., ...
... 7 Hamline University School of Law,s,Health Law Institute ... offer a Health Care Corporate Compliance Certificate,education program. Hamline,s ... the Upper Midwest and one of only four programs ... program is designed to be completed within,one year, with ...
... studies indicate improved IVF procedures may spare patients money & ... ... Calif., May 7 Spurred by recent research,California fertility specialists are ... -- saying newer,and improving in vitro fertilization (IVF) technology tends to ...
Cached Medicine News:Health News:Expectant Moms Offered Free Prenatal Prescription Vitamins at D-FW Area Carnival, Minyard and Sack'n Save Stores 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 3Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2Health News:Fertility Doctors: Studies Suggest Artificial Insemination Increasingly Second Choice 2
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
Inquire...
... are ideal for PCR and ... any work where aerosol contamination ... for pipetting DNA/RNA solutions, infectious ... For applications requiring absolute sterility, ...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Medicine Products: